Business Description
Theriva Biologics Inc
NAICS : 325412
SIC : 2834
ISIN : US87164U1025
Total Employee Number:
16Description
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.91 | |||||
Equity-to-Asset | 0.4 | |||||
Debt-to-Equity | 0.24 | |||||
Debt-to-EBITDA | -0.17 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -14.56 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 61.7 | |||||
3-Year EPS without NRI Growth Rate | 60.1 | |||||
3-Year FCF Growth Rate | 64.7 | |||||
3-Year Book Growth Rate | -82.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 45.5 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.63 | |||||
Quick Ratio | 1.63 | |||||
Cash Ratio | 1.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -289.3 | |||||
Shareholder Yield % | -156.31 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -7254 | |||||
Net Margin % | -7153 | |||||
EBITDA Margin % | -7218.67 | |||||
FCF Margin % | -4768.34 | |||||
OCF Margin % | -4768.34 | |||||
ROE % | -168.6 | |||||
ROA % | -61.2 | |||||
ROIC % | -92.21 | |||||
3-Year ROIIC % | 60.71 | |||||
ROC (Joel Greenblatt) % | -1529.3 | |||||
ROCE % | -88.11 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 33.5 | |||||
PB Ratio | 0.7 | |||||
EV-to-Revenue | 0.08 | |||||
FCF Yield % | -133.52 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Theriva Biologics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.259 | ||
| EPS (TTM) (€) | -2.183 | ||
| Beta | 0.329 | ||
| 3-Year Sharpe Ratio | -1.06 | ||
| 3-Year Sortino Ratio | -1.09 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 2.42 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 2.42 - 2.42 | ||
| Shares Outstanding (Mil) | 45.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Theriva Biologics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Theriva Biologics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 124 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 08:00 | In 32 days | ||
| General meeting for 2026 | 2026-08-03 15:30 | In 24 days | ||
| First quarter earnings results for 2026 | 2026-05-05 | 2.42 (+0.00%) | ||
| Annual report for 2025 | 2026-03-12 | 2.42 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 2.42 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 2.42 (+0.00%) | ||
| General meeting for 2025 | 2025-08-29 15:30 | 2.42 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-11 08:00 | 2.42 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 2.42 (+0.00%) |
Show
Entries
Theriva Biologics Inc Frequently Asked Questions
What is Theriva Biologics Inc(FRA:SFY0)'s stock price today?
The current price of FRA:SFY0 is €2.42. The 52 week high of FRA:SFY0 is €2.42 and 52 week low is €2.42.
When is next earnings date of Theriva Biologics Inc(FRA:SFY0)?
The next earnings date of Theriva Biologics Inc(FRA:SFY0) is 2026-08-11 Est..
Does Theriva Biologics Inc(FRA:SFY0) pay dividends? If so, how much?
Theriva Biologics Inc(FRA:SFY0) does not pay dividend.
Press Release
Articles on Theriva Biologics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers